Alison Tjosvold Milhous
Known title: DirectorCIK: 0001824808
Associated companies
Transaction History
| VIVS | ▲ Buy | Grant | 15,000 | $0 | 1/27/2026 | View on chart |
| VIVS | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 | View on chart |
| VIVS | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 | View on chart |
| VIVS | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing
Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing. Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.